Additionally, we noted that celastrol treatment facilitated the mRNA decay of Claspin and Bcl-2, suggesting that celastrol-mediated decrease of the m6A modification might trigger the mRNA degradation of Claspin and Bcl-2 in pancreatic cancer cells. The gene discussed is BCL2; the disease is pancreatic neoplasm.